Article

You have full text access to this OnlineOpen article

Adriamycin cardiomyopathy—risk factors

  1. Robert A. Minow MD†,
  2. Robert S. Benjamin MD*,
  3. Elisa T. Lee PhD‡,
  4. Jeffrey A. Gottlieb MD§

Article first published online: 29 JUN 2006

DOI: 10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U

Issue

Cancer

Cancer

Volume 39, Issue 4, pages 1397–1402, April 1977

Additional Information

How to Cite

Minow, R. A., Benjamin, R. S., Lee, E. T. and Gottlieb, J. A. (1977), Adriamycin cardiomyopathy—risk factors. Cancer, 39: 1397–1402. doi: 10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U

Author Information

  1. Departments of Developmental Therapeutics and Biomathematics, The University of Texas System Cancer, M.D. Anderson Hospital and Tumor Institute, Houston, TX 77030

  1. †

    1703 Termino Avenue, Long Beach, CA 90804

  2. ‡

    Department of Biostatistics and Epidemiology, University of Oklahoma, Health Sciences Center, Oklahoma City, OK 73104

  1. §

    Deceased.

*Department of Developmental Therapeutics, The University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute, Houston, TX 77030

Publication History

  1. Issue published online: 29 JUN 2006
  2. Article first published online: 29 JUN 2006
  3. Manuscript Received: 14 JUN 1976

Funded by

  • U.S. Public Health Service. Grant Numbers: CA-10379, CA-14538, CA-11520, CA-11430
  • National Cancer Institute, Bethesda, MD 20014. Grant Number: CA-05831

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (525K)

Abstract

The records of 53 patients treated with Adriamycin, 17 of whom developed congestive heart failure and 36 of whom received a similar total dose of Adriamycin without developing congestive heart failure, were analyzed for factors associated with Adriamycin cardiomyopathy. The risk of cardiomyopathy was significantly greater in patients who developed a ≥30% decrease in limb-lead QRS voltage. Concurrent cyclophosphamide and mediastinal radiotherapy lowered the cumulative Adriamycin dose necessary for the development of cardiac toxicity. Uncontrolled hypertension also appears to be a risk factor in potentiating the development of Adriamycin cardiomyopathy at lower doses. Congestive heart failure was more likely to be fatal if it developed shortly after the last dose of Adriamycin. These findings can be utilized to increase the safety of Adriamycin therapy in the future.

Get PDF (525K)